RayKnowChina Research Map
Shortlist0

XiamenXiamen University

Zhongshan Hospital, Xiamen University

厦门大学附属中山医院

Listed for 13 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Zhongshan Hospital, Xiamen University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌2 papers led
  2. Hepatocellular carcinoma肝细胞癌27 papers led
  3. Stomach cancer胃癌30 papers led
  4. Hepatoblastoma肝母细胞瘤0 papers led
  5. Osteosarcoma骨肉瘤3 papers led
  6. Neuroblastoma神经母细胞瘤1 paper led
  7. Multiple myeloma多发性骨髓瘤2 papers led
  8. Beta thalassaemiaβ 地中海贫血2 papers led
  9. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led
  10. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  11. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  12. IgA nephropathyIgA 肾病5 papers led
  13. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 2 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.07%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

3 hospitals in Xiamen for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapy
Papers it led2
  1. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.2024International journal of surgery (London, England)Free full text
  2. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.2023Annals of surgical oncology
All its trials on ClinicalTrials.gov, any status7
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  2. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  3. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  4. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  5. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  6. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  7. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)2
  1. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint
  2. Real-world clinical effectiveness and safety of camrelizumab in esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 27 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
27
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 7720232024: 3320242025: 10102025

2 hospitals in Xiamen for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Neoadjuvant Triple Therapy for Resectable HCC
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06569498

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

  2. Recruiting
    Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06602011

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led27
  1. Preoperative prediction of microvascular invasion and relapse-free survival in hepatocellular Carcinoma ≥3 cm using CT radiomics: Development and external validation.2025BMC medical imagingFree full text
  2. Visualizing enterohepatic circulation in vivo by sensitive 19F MRI with a fluorinated ferrous chelate-based small molecule probe.2025Biomaterials
  3. PSMD14-mediated deubiquitination of CARM1 facilitates the proliferation and metastasis of hepatocellular carcinoma by inducing the transcriptional activation of FERMT1.2025Cell death & diseaseFree full text
  4. Glucose starvation mimetic aldometanib removes immune barriers permitting mice with hepatocellular carcinoma to live to normal ages.2025Cell researchFree full text
  5. Telomere-methylation genes: Novel prognostic biomarkers for hepatocellular carcinoma.2025Clinics and research in hepatology and gastroenterology
  6. Integrating transcriptome and metabolomics analyses of hepatocellular carcinoma to discover novel biomarkers and drug targets.2025Clinics and research in hepatology and gastroenterology
  7. Case Report: Long-term disease-free survival in an advanced hepatocellular carcinoma patient: an exceptional response to PD-1 inhibitor therapy.2025Frontiers in immunologyFree full text
  8. Analysis of different prognoses in two hepatocellular carcinoma patients with pathological complete response after conversion therapy: a case report.2025Journal of medical case reportsFree full text
  9. The role of hypoxia-senescence co-related molecular subtypes and prognostic characteristics in hepatocellular carcinoma.2025Scientific reportsFree full text
  10. Preliminary investigation of nicotinamide N-methyltransferase as an HBV-specific biomarker for hepatocellular carcinoma diagnosis.2025The International journal of biological markers
  11. Generation of virtual monoenergetic images at 40 keV of the upper abdomen and image quality evaluation based on generative adversarial networks.2024BMC medical imagingFree full text
  12. ONC206 targeting ClpP induces mitochondrial dysfunction and protective autophagy in hepatocellular carcinoma cells.2024Neoplasia (New York, N.Y.)Free full text
  13. The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma.2024Scientific reportsFree full text
  14. Identification of key modules and driving genes in nonalcoholic fatty liver disease by weighted gene co-expression network analysis.2023BMC genomicsFree full text
  15. Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1.2023Biochemical pharmacology
  16. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.2023Cancer biology & medicineFree full text
  17. Upregulation of helicase-like transcription factor predicts poor prognosis and facilitates hepatocellular carcinoma progression.2023Human cell
  18. Tumor-associated NK cells facilitate tumor growth via NKp46 in immunocompetent murine hepatocellular carcinoma.2023Immunology letters
  19. CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway.2023Journal of translational medicineFree full text
  20. Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway.2023Liver international : official journal of the International Association for the Study of the Liver
  21. Long non-coding RNA muskelin 1 antisense RNA as a potential therapeutic target in hepatocellular carcinoma treatment.2022BioengineeredFree full text
  22. The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis.2022BioengineeredFree full text
  23. Genome-wide long noncoding RNA and mRNA expression profiles demonstrate associations between exposure to inorganic elements and the risk of developing hepatocellular carcinoma.2021BMC medical genomicsFree full text
  24. Dichloroacetate attenuates the stemness of hepatocellular carcinoma cells via promoting nucleus-cytoplasm translocation of YAP.2021Environmental toxicology
  25. Insulin promotes hepatocarcinoma tumorigenesis by up-regulating PKM2 expression.2021Experimental cell research
  26. RING-finger protein 5 promotes hepatocellular carcinoma progression and predicts poor prognosis.2021Human cell
  27. The Diagnostic Performance of lncRNAs from Blood Specimens in Patients with Hepatocellular Carcinoma: A Meta-Analysis.2021Laboratory medicine
Chinese-language papers (not in the count)1
  1. [Correlation analysis of dynamic enhanced energy spectrum CT parameters with Ki-67 high expression in hepatocellular carcinoma].2023Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status4
  1. Neoadjuvant Triple Therapy for Resectable HCCRecruitingNCT06569498Study siteStart 2024-09
  2. Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)RecruitingNCT06602011Study siteStart 2024-09
  3. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  4. Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 ExpressionStatus unknownNCT01681446Study sitePhase 3Start 2012-08

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 30 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
30
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 3320222023: 5520232024: 6620242025: 10102025

2 hospitals in Xiamen for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNutrition & recoveryImmunotherapy & targeted drugsChemotherapy & combined treatment
Departments in papersRadiology / nuclear medicineRadiation oncologySurgery (general/hepatobiliary/pancreatic)Medical oncology

Over half of these papers are lab or animal studies.

Papers it led30
  1. Vesicle-mediated transport-related gene SEC23A promotes cell proliferation by regulating cell cycle leading to gastric cancer progression.2025Acta biochimica et biophysica SinicaFree full text
  2. METTL10-Mediated PIAS3 Methylation Links Purine Metabolism to Gastric Cancer Progression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.2025Advances in therapyRCTFree full text
  4. Risk factors for pneumonia after radical gastrectomy for gastric cancer: a systematic review and meta-analysis.2025BMC cancerFree full text
  5. Transcriptional profiling reveals H.pylori-associated genes induced inflammatory cell infiltration and chemoresistance in gastric cancer.2025Frontiers in immunologyFree full text
  6. Nuclear export of transmembrane protein PROM2 is specially regulated by CRM1 and affects the sensitivity of ferroptosis in gastric cancer.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  7. Cleavage of CAD by caspase-3 determines the cancer cell fate during chemotherapy.2025Nature communicationsFree full text
  8. Long noncoding RNA MATN1-AS1 contributes to oxaliplatin resistance of gastric cancer cells through miR-518b/ZNF281 axis.2025Naunyn-Schmiedeberg's archives of pharmacology
  9. HSP90/PUS7/THUMPD1 promotes metastasis and cisplatin resistance in gastric cancer cells.2025Scientific reportsFree full text
  10. Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A propensity-matched outcomes study.2025World journal of gastroenterologyFree full text
  11. Inhibition of USP22 by miR-200b-5p represses gastric cancer cell proliferation and migration by targeting the NF-κB signaling pathway.2024Acta biochimica et biophysica SinicaFree full text
  12. The macrophage-associated prognostic gene ANXA5 promotes immunotherapy resistance in gastric cancer through angiogenesis.2024BMC cancerFree full text
  13. Dehydroabietylamine exerts antitumor effects by affecting nucleotide metabolism in gastric cancer.2024CarcinogenesisFree full text
  14. TAGLN2 induces resistance signature ISGs by activating AKT-YBX1 signal with dual pathways and mediates the IFN-related DNA damage resistance in gastric cancer.2024Cell death & diseaseFree full text
  15. Predicting tumor invasion depth in gastric cancer: developing and validating multivariate models incorporating preoperative IVIM-DWI parameters and MRI morphological characteristics.2024European journal of medical researchFree full text
  16. Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer.2024eLifeFree full text
  17. Machine learning models predict the mTOR signal pathway-related signature in the gastric cancer involving 2063 samples of 7 centers.2023AgingFree full text
  18. SOX2-Induced Linc-ROR Upregulation Inhibits Gastric Carcinoma Cell Proliferation and Metastasis Via the miR-580-3p/ANXA10 Pathway.2023Biochemical genetics
  19. Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy.2023Cell reports
  20. CXCR4 Expressed by Tumor-Infiltrating B Cells in Gastric Cancer Related to Survival in the Tumor Microenvironment: An Analysis Combining Single-Cell RNA Sequencing with Bulk RNA Sequencing.2023International journal of molecular sciencesFree full text
  21. HSPA6, a novel prognostic and therapeutic biomarker, associated with Ming classification in gastric cancer.2023Journal of clinical laboratory analysisFree full text
  22. MicroRNA-18 facilitates the stemness of gastric cancer by downregulating HMGB3 though targeting Meis2.2022BioengineeredFree full text
  23. Downregulation of lncRNA FOXD2-AS1 Confers Radiosensitivity to Gastric Cancer Cells via miR-1913/SETD1A Axis.2022Cytogenetic and genome research
  24. Laparoscopic-Assisted Natural Orifice Specimen Extraction Gastrectomy Using an Auxiliary Incision-Free Tube for Gastric Cancer.2022The Journal of surgical research
  25. Linc00467 promotion of gastric cancer development by directly regulating miR-7-5p expression and downstream epidermal growth factor receptor.2021BioengineeredFree full text
  26. MicroRNA miR-425 promotes tumor progression by inhibiting Dickkopf-related protein-3 in gastric cancer.2021BioengineeredFree full text
  27. Quantitative study of preoperative staging of gastric cancer using intravoxel incoherent motion diffusion-weighted imaging as a potential clinical index.2021European journal of radiology
  28. Inhibition of protein PMP22 enhances etoposide-induced cell apoptosis by p53 signaling pathway in Gastric Cancer.2021International journal of biological sciencesFree full text
  29. Development and External Validation of a Nomogram for Predicting Overall Survival in Stomach Cancer: A Population-Based Study.2021Journal of healthcare engineeringFree full text
  30. Candida albicans disorder is associated with gastric carcinogenesis.2021TheranosticsFree full text
Chinese-language papers (not in the count)2
  1. [Specimen extraction through natural orifices with Cai tubes in gastrointestinal surgery: a single-institute series of 234 cases].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Value of dual-layer spectral detector CT in preoperative prediction of lymph node metastasis of gastric cancer].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status9
  1. Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal CancerStatus unknownNCT04067986Lead sponsorPhase 1/Phase 2Start 2019-08
  2. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  3. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  4. Evaluating Diagnostic Performance of Spectra IMDx System for Detection of Gastric Cancer and Precancerous LesionsStatus unknownNCT04835246Study siteN/AStart 2019-10
  5. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GCStatus unknownNCT04638959Study siteStart 2019-09
  6. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  7. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  8. Nasal Endoscopic Screening and Risk Assessment for Early Gastric CancerStatus unknownNCT04989153Study siteStart 2016-03
  9. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Xiamen for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 002025

7 hospitals in Xiamen for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Xiamen for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

2 hospitals in Xiamen for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDrug combinationsRelapse & resistanceDiagnosis, MRD & risk

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Xiamen for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led no English-language PubMed papers on neuromyelitis optica spectrum disorder in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

3 hospitals in Xiamen for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

  2. Not yet recruiting
    Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07266051

    Age 18 years to Not stated (registered criteria)

    Led by Xiamen Hospital; 3 listed hospitals as study sitesShanghai, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)Not yet recruitingNCT07266051Study siteStart 2025-12
  2. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Xiamen for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Xiamen for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Analysis of clinical characteristics of amyotrophic lateral sclerosis patients initially diagnosed with abnormal laryngeal function].2024Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 5 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.7%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

4 hospitals in Xiamen for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Xiamen for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

厦门大学附属中山医院

Zhongshan Hospital, Xiamen University

厦门

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Zhongshan Hospital of Xiamen University; Zhongshan Hospital; Zhongshan Hospital Xiamen University; Zhongshan Hospital Affiliated to Xiamen University; Affiliated Zhongshan Hospital of Xiamen University; Affiliated Zhongshan Hospital

Suggest a correctionDownload the data